<?xml-stylesheet type="text/xsl" href="https://www.vetsurgeon.org/utility/feedstylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>New company to develop monoclonal antibody therapies for companion animals</title><link>/b/veterinary-news/posts/new-company-to-develop-monoclonal-antibody-therapies-for-companion-animals</link><description> A new company, PetMedix , has been set up to develop new monoclonal antibody therapies for cats and dogs which could, it says, transform a wide range of veterinary treatment options, offering more effective treatment with fewer side-effects. 
 The company</description><dc:language>en-US</dc:language><generator>Telligent Community 10</generator></channel></rss>